Clinical Trial Update: Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating rapamycin plus estradiol versus rapamycin-eluting stents to reduce restenosis in coronary heart disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• ESTRADIOL (Estradiol)
• Rapamycin (Sirolimus) (sirolimus)
• Rapamycin-eluting stent (sirolimus-eluting stent)

Snippet

Sponsor: Deutsches Herzzentrum Muenchen | Conditions: Coronary Heart Disease | Phase 4 | Status: COMPLETED